Filters
Erectile dysfunction (ED) is prevalent in men with chronic kidney disease (CKD), reports a recent meta-analysis.
Silodosin, which helps patients achieve anejaculation, may be an effective treatment for postorgasmic illness syndrome (POIS), a recent study has found. Nevertheless, POIS remains an understudied condition with debilitating consequences on patients and their partners, underscoring the need for further investigations.
Adding the lutetium-labelled PSMA*-617 (177Lu PSMA-617) targeted radioligand therapy to standard of care (SOC) led to significant extension of radiographic progression-free survival (rPFS) and overall survival (OS) compared with SOC alone in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed after treatment with chemotherapy and androgen inhibitors, according to the VISION trial presented at ASCO 2021.
Low-dose-rate brachytherapy (LDR-BT) provides a better biochemical failure-free survival (bFFS) rate than external beam radiation therapy (EBRT) in Asian men with intermediate-risk prostate cancer, according to a recent Singapore study.
A recent study has demonstrated the safety and efficacy of atezolizumab in under-represented individuals with metastatic urinary tract carcinoma, specifically those with older age, renal impairment, or upper tract urothelial carcinoma.
Urogenital infections with Chlamydia trachomatis, Ureaplasma spp., and Mycoplasma hominis appear to increase the risk of couple’s primary infertility, reveals a recent study.
Men who are born small for gestational age (SGA) or with low birthweight (LBW) may be at a disadvantage when it comes to fertility or the prospect of becoming biological fathers, and this becomes more evident as men get older, according to a study.
The increasing use of social media and online reviews has made it easier for patients to comment publicly—on Facebook and Google reviews, for instance—on the care they receive. Positive comments are heartening for any healthcare professional to read.
Salvage cystectomy following trimodality therapy for intravesical recurrence demonstrates similar intraoperative and early complication rate to primary cystectomy and primary cystectomy with prior history of nontrimodality therapy abdominal or pelvic radiotherapy, reports a study.
Intense neoadjuvant hormone therapy in high-risk localized prostate cancer is associated with favourable pathologic responses (tumour <5 mm) in nearly one of five patients, a phase II study has shown. In addition, pathologic responses are comparable between treatment groups.
